Shares of drugmaker Viatris VTRS.O rise 2% to $18 premarket
The company reports Q2 adjusted profit of 69 cents per share versus analysts' average estimate of 60 cents per share, according to LSEG data
Q2 revenue of $3.76 billion beats analysts' average expectation of $3.68 billion, helped by strong demand for its branded drugs and strength in the Greater China region
The company expects annual revenue of $14.55 billion to $14.95 billion compared with its previous expectation between $14.45 billion and $14.95 billion
The company expects annual adjusted profit per share of $2.45 to $2.59 versus its prior estimate of $2.33 and $2.47
Up to the last close, the stock was up 41.8% year to date
VTRS•
